NCT04282967

Brief Summary

This is a single-arm pilot study to evaluate the use of web-based video conferencing as a method of exercise training delivery. This study will include 10 female breast cancer survivors and 10 male prostate cancer survivors. For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at P25-P50 for early_phase_1 prostate-cancer

Timeline
Completed

Started Jul 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 25, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

July 7, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2023

Completed
Last Updated

April 11, 2023

Status Verified

April 1, 2023

Enrollment Period

2.7 years

First QC Date

February 20, 2020

Last Update Submit

April 10, 2023

Conditions

Keywords

ExerciseBreast Cancer SurvivorProstate Cancer Survivor

Outcome Measures

Primary Outcomes (4)

  • Attendance

    Explore adherence to intervention delivery measured through attendance (frequency of Skype sessions attended and fully completed)

    12 weeks

  • Adherence

    Explore adherence to intervention delivery measured through retention (participation from baseline through final assessment)

    12 weeks

  • Patient consent

    Explore adherence to intervention delivery measured through percentage of patients approached who sign consent

    1 day

  • Manipulation check

    Explore adherence to intervention delivery measured through scores on manipulation check after each session (2 questions asked by exercise physiologist on sound and visual clarity of the session)

    12 weeks

Secondary Outcomes (13)

  • Changes in oxygen uptake (baseline - mid-study visit)

    12 weeks

  • Changes in oxygen uptake (mid-study visit - end of study visit)

    12 weeks

  • Changes in oxygen uptake (baseline - end of study visit)

    24 weeks

  • Changes in strength test (baseline - mid-study visit)

    12 weeks

  • Changes in strength test (mid-study visit - end of study visit)

    12 weeks

  • +8 more secondary outcomes

Study Arms (1)

Exercise

EXPERIMENTAL

For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Behavioral: Exercise

Interventions

ExerciseBEHAVIORAL

For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Exercise

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male previously diagnosed with prostate cancer or female previously diagnosed with breast cancer.
  • For breast cancer, minimum of 3 months post-active treatment completion. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable.
  • For prostate cancer, minimum of 3 months post-active treatment completion. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable, except for androgen receptor-targeted therapies (such as enzalutamide, apalutamide, darolutamide, or abiraterone). Patients currently on active surveillance are eligible even if they have not received prior anti-cancer treatment.
  • Has access to tablet, laptop, or desktop computer with video capabilities connected to the internet with a screen at least 13 inches across.
  • Physically able to complete modified Bruce submaximal treadmill test, leg strength test, grip strength test, and InBody per patient self-assessment.
  • Physician clearance to participate in this study. Can be done through review of patients' medical records.
  • Ability to read, write, and understand English.
  • Has a chair at home to use for exercise that is not on wheels and has a solid back (not a reclining chair).
  • Ambulatory without assistance.
  • Has a clear 5 x 6-foot space at home in which to exercise.
  • Age \>18 years.
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

You may not qualify if:

  • Active treatment planned within the next 6 months. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable, except for AR-targeted therapies for prostate cancer.
  • Known metastatic disease.
  • Grade 3 or higher peripheral neuropathy.
  • Major surgery within 3 months of baseline visit.
  • Positive pregnancy test for women of child-bearing potential.
  • Answers yes to any question on the Physical Activity Readiness Questionnaire unless study participation is cleared by a physician.
  • Known allergy to Fitbit device.
  • Currently meeting physical activity guidelines (score of \>23 on Godin-Shephard Leisure-Time Physical Activity Questionnaire).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cedars Sinai Medical Center

Los Angeles, California, 90048, United States

Location

MeSH Terms

Conditions

Prostatic NeoplasmsMotor Activity

Interventions

Exercise

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Celina Shirazipour, PhD

    Cedars-Sinai Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

February 20, 2020

First Posted

February 25, 2020

Study Start

July 7, 2020

Primary Completion

March 30, 2023

Study Completion

March 30, 2023

Last Updated

April 11, 2023

Record last verified: 2023-04

Locations